Comparative Pharmacology
Head-to-head clinical analysis: DESOGEN versus LOARGYS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESOGEN versus LOARGYS.
DESOGEN vs LOARGYS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.
LOARGYS is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.
100 mg orally twice daily.
None Documented
None Documented
The terminal elimination half-life of etonogestrel is approximately 30-41 hours. This long half-life supports once-daily dosing for contraceptive efficacy.
Terminal elimination half-life: 12-18 hours (prolonged in renal impairment).
Desogestrel is primarily metabolized to its active metabolite etonogestrel, which is extensively metabolized and excreted as conjugates. About 50-60% is excreted via urine and 30-40% via feces. Less than 1% is excreted unchanged.
Primarily renal (70-80% unchanged; 10-15% as metabolites); biliary/fecal (5-10%).
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive